These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36201269)

  • 21. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
    Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
    Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
    Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
    Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
    Ma T; Chen X; Wang M
    Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
    Taha EA; Lee J; Hotta A
    J Control Release; 2022 Feb; 342():345-361. PubMed ID: 35026352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
    Ma Y; Deng L; Li S
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing.
    Xiu K; Saunders L; Wen L; Ruan J; Dong R; Song J; Yang D; Zhang J; Xu J; Chen YE; Ma PX
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
    Dong W; Kantor B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
    Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
    Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
    Bae T; Hur JW; Kim D; Hur JK
    Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
    Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
    Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Delivery Challenge of Genome Editing in Human Epithelia.
    Calderón M; Hedtrich S
    Adv Healthc Mater; 2021 Oct; 10(19):e2100847. PubMed ID: 34165913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR-Cas systems: Challenges and future prospects.
    Gohil N; Bhattacharjee G; Lam NL; Perli SD; Singh V
    Prog Mol Biol Transl Sci; 2021; 180():141-151. PubMed ID: 33934835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biogenic materials for CRISPR delivery and therapeutics.
    Yang K; Qian J; Zhang C; Wang Z; Huang Q; Shi G; Zhang Z; Yang Y; Han X
    Biomater Sci; 2023 May; 11(9):3016-3033. PubMed ID: 36897609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.